LOGIN  |  REGISTER
Viking Therapeutics

Syra Health To Discuss Third Quarter 2024 Financial Results

October 22, 2024 | Last Trade: US$0.08 0.00 0.00
  • Conference call will be held on Tuesday, October 29 at 9:00 AM ET

CARMEL, Ind., Oct. 22, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company"), a healthcare technology company powering better health by providing meaningful solutions, announced today that it will report financial results for the three months ended September 30, 2024, on Tuesday, October 29, 2024, before the market opens. The Company has scheduled a conference call that same day, October 29, at 9:00 a.m. ET, to review the results.

Interested parties can access the conference call via Internet webcast, which is available in the Investors section of the Company's website at https://dev.syrahealth.com/ir/presentations/q3-2024-earnings-call.

Investors who would like to submit a question to be addressed on the call should email the question to This email address is being protected from spambots. You need JavaScript enabled to view it..

A webcast replay will be available in the Investors section of the Company's website at https://dev.syrahealth.com/ir/presentations/q3-2024-earnings-call.

ABOUT SYRA HEALTH CORP.

Syra Health leads the charge in addressing the toughest challenges in healthcare, from behavioral and mental health to population health, digital transformation, health education, and workforce development. Our technology-driven solutions focus on prevention, accessibility, and affordability, ensuring that every patient and provider gets the support they need. We proudly partner with payers, providers, life sciences organizations, academic institutions, and government entities to advance healthcare and improve outcomes. Learn more about our mission and services at www.syrahealth.com.

Contact
For Media or Investor Inquiries:
Christine Drury
Syra Health
IR/PR Director
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page